DFM Platform
DFM Funding Monitor

Novel precision fermentation process to produce animal-free bioidentical ovalbuminbroad

Bioalbumen · Horizon Europe grant · 2025-01-01–2026-12-31

EC contribution

€2,499,999

Total cost

€0

Beneficiaries

1
About the data

Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2024-ACCELERATOR-02 · scheme HORIZON-EIC-ACC · topic HORIZON-EIC-2024-ACCELERATORCHALLENGES-04. CORDIS record →

Objective

Eggs are critically important in the global food system due to functional and nutritional properties; yet the egg market and supply chains are in crisis due to cage-free requirements and avian flu. Onego Bio will make it possible to manufacture egg protein entirely animal-free. We developed a highly-scalable precision fermentation process using the patented Trichoderma reesei cellular-based production to produce animal-free ovalbumin. We produce bioidentical egg protein with cost parity and 87% lower CO2 emissions compared to traditional animal-derived eggs.Ovalbumin is the most important egg protein, responsible for the essential ingredient performance. This single protein ovalbumin can solve all current challenges in the egg market and supply chain.Our product, Bioalbumen provides the nutritional and functional upsides of egg protein, without the environmental, ethical and safety-related drawbacks. Our manufacturing method stabilises the food supply chain and increases food security.

Beneficiaries (1)

OrganisationCountryRoleEC contributionSME
ONEGO BIO LTD DFM profile FI coordinator €2,499,999 Yes

Get the DFM funding briefing — free

New EU defence calls, tenders and awards in your inbox.

Countries
Sectors
Sources

We store your email only to send the DFM briefing/alerts and to add you to DFM Analysis. Unsubscribe anytime.

Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.